Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
You may also be interested in...
Lundbeck Pins Hopes On New Product Launches, Ex-Europe Growth To Reverse Revenue Drain
Denmark's CNS drugs specialist Lundbeck expects three 2013 product launches, a portfolio of new medicines and a marketing drive into markets outside anemic Europe to help offset lost revenue and profits caused by escitalopram patent expiry in the U.S. and Europe.
Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market
Two firms will collaborate on the development and marketing of new psychiatric products, including an intramuscular depot formulation of the blockbuster antipsychotic medicineLundbeck Inc. , Abilify.